609 related articles for article (PubMed ID: 28075558)
1. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
Gause KT; Wheatley AK; Cui J; Yan Y; Kent SJ; Caruso F
ACS Nano; 2017 Jan; 11(1):54-68. PubMed ID: 28075558
[TBL] [Abstract][Full Text] [Related]
2. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?
Marasini N; Kaminskas LM
Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591
[TBL] [Abstract][Full Text] [Related]
3. Immunological basis for enhanced immunity of nanoparticle vaccines.
Kelly HG; Kent SJ; Wheatley AK
Expert Rev Vaccines; 2019 Mar; 18(3):269-280. PubMed ID: 30707635
[TBL] [Abstract][Full Text] [Related]
4. Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses.
Vasou A; Sultanoglu N; Goodbourn S; Randall RE; Kostrikis LG
Viruses; 2017 Jul; 9(7):. PubMed ID: 28703784
[TBL] [Abstract][Full Text] [Related]
5. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.
Jain S; O'Hagan DT; Singh M
Expert Rev Vaccines; 2011 Dec; 10(12):1731-42. PubMed ID: 22085176
[TBL] [Abstract][Full Text] [Related]
6. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.
Maisonneuve C; Bertholet S; Philpott DJ; De Gregorio E
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12294-9. PubMed ID: 25136133
[TBL] [Abstract][Full Text] [Related]
7. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
8. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
9. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants.
Miyaji EN; Carvalho E; Oliveira ML; Raw I; Ho PL
Braz J Med Biol Res; 2011 Jun; 44(6):500-13. PubMed ID: 21584443
[TBL] [Abstract][Full Text] [Related]
10. Liposomal vaccine delivery systems.
Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.
Kaur A; Kannan D; Mehta SK; Singh S; Salunke DB
Expert Opin Ther Pat; 2018 Nov; 28(11):837-847. PubMed ID: 30280939
[TBL] [Abstract][Full Text] [Related]
12. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.
Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD
Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651
[TBL] [Abstract][Full Text] [Related]
13. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary vaccine delivery.
Lu D; Hickey AJ
Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
[TBL] [Abstract][Full Text] [Related]
16. Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines.
Benne N; van Duijn J; Kuiper J; Jiskoot W; Slütter B
J Control Release; 2016 Jul; 234():124-34. PubMed ID: 27221070
[TBL] [Abstract][Full Text] [Related]
17. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle vaccines.
Zhao L; Seth A; Wibowo N; Zhao CX; Mitter N; Yu C; Middelberg AP
Vaccine; 2014 Jan; 32(3):327-37. PubMed ID: 24295808
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles and Vaccine Development.
Kheirollahpour M; Mehrabi M; Dounighi NM; Mohammadi M; Masoudi A
Pharm Nanotechnol; 2020; 8(1):6-21. PubMed ID: 31647394
[TBL] [Abstract][Full Text] [Related]
20. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
